Southern Capital Advisors LLC Acquires Shares of 3,107 Johnson & Johnson (NYSE:JNJ)

Southern Capital Advisors LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,107 shares of the company’s stock, valued at approximately $532,000.

Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Mercer Global Advisors Inc. ADV raised its stake in shares of Johnson & Johnson by 4.5% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 344,918 shares of the company’s stock worth $59,005,000 after acquiring an additional 14,872 shares during the last quarter. Revolve Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $2,574,000. Wealth Dimensions Group Ltd. lifted its stake in shares of Johnson & Johnson by 1.3% during the fourth quarter. Wealth Dimensions Group Ltd. now owns 15,953 shares of the company’s stock valued at $2,729,000 after acquiring an additional 197 shares during the period. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Johnson & Johnson by 1.9% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 69,688 shares of the company’s stock valued at $11,922,000 after buying an additional 1,275 shares during the period. Finally, Hendershot Investments Inc. lifted its stake in Johnson & Johnson by 30.6% in the fourth quarter. Hendershot Investments Inc. now owns 138,680 shares of the company’s stock valued at $23,724,000 after buying an additional 32,487 shares during the period. 67.84% of the stock is owned by institutional investors.

In related news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total transaction of $4,173,776.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.35% of the company’s stock.

JNJ stock traded up $6.04 during mid-day trading on Tuesday, reaching $183.70. The company had a trading volume of 681,286 shares, compared to its average volume of 7,890,662. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12. The stock has a 50 day simple moving average of $172.50 and a two-hundred day simple moving average of $168.01. The company has a market capitalization of $483.00 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 2.71 and a beta of 0.72. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $184.20.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.61 by $0.06. Johnson & Johnson had a return on equity of 37.46% and a net margin of 22.26%. The company had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. During the same period last year, the firm posted $2.59 earnings per share. The business’s revenue was up 5.0% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.48 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.46%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date is Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 54.29%.

Several equities analysts have weighed in on JNJ shares. The Goldman Sachs Group increased their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their target price for the company from $180.00 to $183.00 in a research note on Wednesday, March 16th. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. StockNews.com assumed coverage on Johnson & Johnson in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Finally, Raymond James increased their price objective on Johnson & Johnson from $185.00 to $195.00 and gave the stock an “outperform” rating in a report on Thursday, April 14th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $184.57.

About Johnson & Johnson (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.